Internal Medicine, Medical Oncology · La Jolla, CA
NPI
1396994604
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
9850 Genesee Ave Ste 560
La Jolla, CA, 92037
Phone (858) 552-1410
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
113,590 services
Medicare patients, 2024
419
Average age 76
Drug cost, 2024
$3.5M
1,083 prescriptions
Company payments, 2025
$5,658
From 46 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Edna I Flores was code Q5125 (injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram), 23,520 times for 12 patients. In total Edna I Flores billed 113,590 services in 130 codes, and Medicare paid $1.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-01-27.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 23,520 | 12 | $0.38 | $8,991 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 20,800 | 39 | $2.31 | $48K |
| J0897 Injection, denosumab, 1 mg | Office | 8,221 | 51 | $20.78 | $171K |
| J0185 Injection, aprepitant, 1 mg | Office | 6,110 | 17 | $1.34 | $8,197 |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 2,800 | 15 | $4.36 | $12K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,300 | 13 | $15.82 | $21K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,064 | 39 | $0.09 | $96.39 |
| 85025 Blood Count | Office | 615 | 132 | $7.61 | $4,680 |
| 36415 Venipuncture Blood Collection | Office | 538 | 135 | $8.65 | $4,654 |
| Q5127 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | Office | 516 | 21 | $257.67 | $133K |
| 96372 Injection Administration | Office | 403 | 144 | $12.04 | $4,851 |
| 99214 Office E&M - Established | Office | 377 | 157 | $99.31 | $37K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 270 | 11 | $0.78 | $210 |
| 99213 Office E&M - Established | Office | 224 | 140 | $68.86 | $15K |
| 96367 Intravenous Infusion, Hydration | Office | 171 | 49 | $25.12 | $4,295 |
By year: 2022 $1.3M for 125,871 services; 2023 $1.6M for 117,833 services; 2024 $1.5M for 113,590 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 615 | 132 | $7.61 | $4,680 |
| 36415 Venipuncture Blood Collection | 538 | 135 | $8.65 | $4,654 |
| 80053 Clinical Chemistry | 18 | 14 | $10.35 | $186 |
Medicare prescription drug claims, 2024
In 2024, the drug Edna I Flores prescribed most often to Medicare patients was Anastrozole, with 205 prescriptions and refills. In total Edna I Flores wrote 1,083 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 205 | 513 | 60 | $4,376 |
| Tamoxifen Citrate Generic | 66 | 125 | 15 | $1,477 |
| Gabapentin Generic | 39 | 41 | Under 11 | $286 |
| Letrozole Generic | 39 | 75 | Under 11 | $762 |
| Prochlorperazine Maleate Generic | 37 | 39 | 23 | $673 |
| Ondansetron Odt Ondansetron | 32 | 34 | 25 | $484 |
| Eliquis Apixaban | 27 | 27 | Under 11 | $15K |
| Exemestane Generic | 26 | 60 | 11 | $6,592 |
| Lenalidomide Generic | 25 | 25 | Under 11 | $384K |
| Prednisone Generic | 25 | 32 | 14 | $173 |
| Hydroxyurea Generic | 19 | 35 | Under 11 | $330 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 19 | 19 | Under 11 | $70.11 |
| Tagrisso Osimertinib Mesylate | 18 | 18 | Under 11 | $302K |
| Revlimid Lenalidomide | 18 | 18 | Under 11 | $277K |
| Valacyclovir Valacyclovir Hcl | 17 | 23 | Under 11 | $266 |
Brand drugs: 199 claims; generic drugs: 884 claims; opioid claims: 52.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Edna I Flores $5,658 ($5,658 in general payments such as food, travel and fees) from 46 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,188.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 19 | $1,188 |
| AstraZeneca Pharmaceuticals LP AZN | 26 | $710 |
| Genzyme Corporation SNY | 8 | $371 |
| E.R. Squibb & Sons, L.L.C. BMY | 11 | $289 |
| Merck Sharp & Dohme LLC MRK | 9 | $238 |
| Pfizer Inc. PFE | 12 | $237 |
| Alexion Pharmaceuticals, Inc. AZN | 6 | $194 |
| Gilead Sciences, Inc. GILD | 10 | $187 |
| Exelixis Inc. EXEL | 7 | $157 |
| Celgene Corporation BMY | 5 | $142 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.